{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (R2PD) of TORC1/2 inhibitor MLN0128, determined according to incidence of dose-limiting toxicity, as graded using the National Cancer Institute (NCI) CTCAE version 4.0","groups":[{"description":"Participants enrolled onto Stage 1 - Dose escalation to estimate MTD/RP2D","id":"OG000","title":"Stage 1: Dose Escalation to Estimate MTD/RP2D"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"28 days","title":"Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (R2PD) of Daily Oral MLN0128 When Administered With Bevacizumab","type":"PRIMARY","unitOfMeasure":"mg/day"}